BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company focused on phage therapy, developing proprietary bacteriophage-based product candidates designed to target and destroy disease-causing bacteria across dermatology and infectious disease indications. The company completed its business combination in 2019 with Chardan Healthcare Acquisitions Corp., a blank-check special purpose acquisition company sponsored by an affiliate of Chardan Capital Markets, LLC. BiomX has remained listed on NYSE American and continues to advance its pipeline of phage-based therapeutics through clinical development; the company filed an amended annual report on Form 10-K/A in April 2026. For full filing history, pipeline status, and SPAC transaction data on BiomX, sign up at SpacDesk.